En este contexto surgió en 2014 el término, de difícil traducción al español, desreanimación o desresucitación (deresuscitation), que se define como la eliminación activa de fluidos de un paciente con sobrecarga de fluidos, bien mediante fármacos o por ultrafiltración. Relacionado con él está el de “desescalada”, que se relaciona con la reducción progresiva de la cantidad de fluidos que se administran a un paciente. El artículo que traemos hoy, publicado en 2022 por cinco intensivistas de diferentes países, pretende (y creemos que consigue) explicar todo lo que debemos conocer sobre los efectos adversos de la administración excesiva de fluidos y cómo y cuándo comenzar, y finalizar, la desreanimación. Enlace de descarga: https://drive.google.com/file/d/1Jgy-MbgxClDYF-9b8bUuwi6p3k-O_tGx/view?usp=sharing
While fluid administration
is one of the most common therapeutic interventions in critical care, it’s
not harmless at all. Fluids should be regarded as drugs with specific
indications, contraindications, and potential adverse effects. The renewed
concept of “fluid stewardship”, analogous to antibiotic stewardship, focusses
on the 4 D’s (drug, dose, duration, and de-escalation), the 4 questions (when
to start and when to stop fluid therapy, and when to start and when to stop
fluid removal), the 4 indications (resuscitation, maintenance, replacement and
nutrition), and the conceptual ROSE model
describing 4 fluid phases (resuscitation, optimization, stabilization and
evacuation).
The term deresuscitation was coined in 2014 and defined as active fluid removal in patients with fluid overload using drugs and/or ultrafiltration (UF). The term ‘de-escalation’ relates more to reducing the amount and rate of previously started fluid administration. The article web ring today, published in 2022 for five intensive care doctors from different countries, pretends (succesfully, we think) to explain all we should know about the adverse effects of the fluid overload and how and when to start (and finish) the deresuscitation. Download link: https://drive.google.com/file/d/1Jgy-MbgxClDYF-9b8bUuwi6p3k-O_tGx/view?usp=sharing
No hay comentarios:
Publicar un comentario